Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours (British Journal of Cancer, (2019), 120, 6, (612-620), 10.1038/s41416-019-0389-6)

César Serrano, Adrián Mariño-Enríquez, Derrick L. Tao, Julia Ketzer, Grant Eilers, Meijun Zhu, Channing Yu, Aristotle M. Mannan, Brian P. Rubin, George D. Demetri, Chandrajit P. Raut, Ajia Presnell, Arin McKinley, Michael C. Heinrich, Jeffrey T. Czaplinski, Ewa Sicinska, Sebastian Bauer, Suzanne George, Jonathan A. Fletcher

Research output: Contribution to journalComment/debatepeer-review

2 Scopus citations

Abstract

The additional information of this manuscript originally stated that the authors declare no competing interests. This statement was incorrect, and should instead have stated the following: M.C.H. has the following competing interests to declare: Equity interest at Molecular MD; Consulting at Molecular MD, Blueprint Medicines, Deciphera Pharmaceuticals; Expert Testimony at Novartis; Licensed patent with royalty payments at Novartis. The remaining authors have no competing interests to declare. The authors apologise for any convenience this may have caused.

Original languageEnglish (US)
Pages (from-to)281
Number of pages1
JournalBritish Journal of Cancer
Volume121
Issue number3
DOIs
StatePublished - Jul 30 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours (British Journal of Cancer, (2019), 120, 6, (612-620), 10.1038/s41416-019-0389-6)'. Together they form a unique fingerprint.

Cite this